Sarepta Therapeutics buy tamam
Start price
09.01.18
/
50%
€48.59
Target price
04.11.21
€153.34
Performance (%)
57.44%
End price
05.11.21
€76.50
Summary
This prediction ended on 05.11.21 with a price of €76.50. With a performance of 57.44% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sarepta Therapeutics | 2.685% | 2.685% | -84.102% | -84.962% |
| iShares Core DAX® | 0.323% | 2.208% | 21.610% | 72.184% |
| iShares Nasdaq 100 | 0.145% | -0.987% | 5.603% | 112.977% |
| iShares Nikkei 225® | 0.091% | -1.421% | 12.897% | 46.571% |
| iShares S&P 500 | 0.371% | -0.469% | 3.470% | 68.947% |
Comments by tamam for this prediction
In the thread Sarepta Therapeutics diskutieren
Sarepta continues to be a core buy in biotech
In today´s investor update management guided for fourth quarter revenue of $57.3 million and full year 2018 Exondys 51 revenue in the range of $295 million to $305 million (roughly double that of 2017).
tamam stimmt am 09.01.2018 der Outperform-Einschätzung der institutionellen Analysten zu.
In the thread Trading Sarepta Therapeutics
Die von tamam gewählte maximale Laufzeit wurde überschritten